T3 PHARMACEUTICALS, Switzerland
nominated by the University of Basel
Breaking the Wall of Cancer Using Engineered Microbes
presented by Dr. Simon Ittig
Startup from Switzerland, T3 Pharmaceuticals, wins the Falling Walls Venture Science Award for its next-generation cancer therapy
Berlin, November 8th 2018. Swiss start-up T3 Pharmaceuticals has been named the "Falling Walls Science Startup of the Year 2018". Its product, a protein delivery technology based on the use of live bacteria, has the capacity to grow specifically in solid tumors, thus helping to treat cancer patients more efficiently.
"T3 Pharmaceuticals impressed the jury with its novel delivery system of bacteria which ensures that solid tumors are accessible and treatment can begin regardless of the type of tumor", said Dr. Stefan von Holtzbrinck, CEO of the Holtzbrinck Publishing Group and head of the Falling Walls Venture Jury, explaining the jury’s choice of the startup from Switzerland. The winner gets the chance to present again on the grand stage of the Falling Walls Conference.
A total of 23 science based startups from around the world were invited to present their business ideas at Falling Walls Venture in Berlin. Among the participants were companies based in Russia, Germany, India, Canada, Switzerland, Great Britain and Mexico. Each company had five minutes to present their business model to the international jury of entrepreneurs, scientists and venture capitalists.
Read more about the Falling Walls Science Start-Up of the Year 2018 on our blog Falling Walls Fragments (link).